drugset / Trial / NCT00856713

Clearance of NRL972 in Patients With Cirrhosis and in Healthy Volunteers

NCT00856713

Phase 1 Completed 72 enrolled Norgine
Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

A study in healthy volunteers and patients with liver cirrhosis to assess the effects of age, gender, and stable liver disease on the clearance of cholyl-lysyl-fluorescein (NRL972)

Timeline

Start
2006-03
Primary completion
2006-08
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject FLUORESCEIN LISICOL Diagnostic / imaging agent 2 mg Intravenous

Indications